HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Li, Guangdi ^a   Verheyen, Jens ^b   Theys, Kristof ^a   Piampongsant, Supinya ^a   Van Laethem, Kristel ^a   Vandamme, Anne Mieke ^a,c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Drug resistance; Gag amino acid substitution; HIV 1 subtype; Protease; Protease inhibitor

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; FOSAMPRENAVIR PLUS RITONAVIR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR PLUS RITONAVIR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; MAJOR CLINICAL STUDY; NONHUMAN; SEQUENCE ALIGNMENT; CHEMISTRY; CLASSIFICATION; HIV INFECTIONS; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84909999714     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0079-7     Document Type: Article

References (22)

1. Larrouy L, Vivot A, Charpentier C, Benard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients. AIDS 2013, 27:69-80. 10.1097/QAD.0b013e32835a10d8, 23018441.
2. Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D, Group AS. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients. Antimicrob Agents Chemother 2010, 54:2910-2919. 10.1128/AAC.00194-10, 20439606.
3. Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res 2010, 85:59-74. 10.1016/j.antiviral.2009.10.003, 19853627.
4. Fun A, Wensing AM, Verheyen J, Nijhuis M. Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology 2012, 9:63. 10.1186/1742-4690-9-63, 22867298.
5. Larrouy L, Charpentier C, Landman R, Capitant C, Chazallon C, Yeni P, Peytavin G, Damond F, Brun-Vezinet F, Descamps D. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen. AIDS 2011, 25:2143-2148. 10.1097/QAD.0b013e32834cabb9, 21904187.
6. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM. Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS 2010, 24:1651-1655. 10.1097/QAD.0b013e3283398216, 20597164.
7. Knops E, Kemper I, Schulter E, Pfister H, Kaiser R, Verheyen J. The evolution of protease mutation 76 V is associated with protease mutation 46I and gag mutation 431 V. AIDS 2010, 24:779-781. 10.1097/QAD.0b013e328336784d, 20139751.
8. Bally F, Martinez R, Peters S, Sudre P, Telenti A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 2000, 16:1209-1213. 10.1089/08892220050116970, 10957718.
9. Ghosn J, Delaugerre C, Flandre P, Galimand J, Cohen-Codar I, Raffi F, Delfraissy JF, Rouzioux C, Chaix ML. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS One 2011, 6:e24798. 10.1371/journal.pone.0024798, 21949754.
10. Knops E, Daumer M, Awerkiew S, Kartashev V, Schulter E, Kutsev S, Brakier-Gingras L, Kaiser R, Pfister H, Verheyen J. Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. J Antimicrob Chemother 2010, 65:1472-1476. 10.1093/jac/dkq129, 20430786.
11. Rossi AH, Rocco CA, Mangano A, Sen L, Aulicino PC. Sequence variability in p6 gag protein and gag/pol coevolution in human immunodeficiency type 1 subtype F genomes. AIDS Res Hum Retroviruses 2013, 29:1056-1060. 10.1089/aid.2012.0311, 23458243.
12. Libin P, Beheydt G, Deforche K, Imbrechts S, Ferreira F, Van Laethem K, Theys K, Carvalho AP, Cavaco-Silva J, Lapadula G, Torti C, Assel M, Wesner S, Snoeck J, Ruelle J, De Bel A, Lacor P, De Munter P, Van Wijngaerden E, Zazzi M, Kaiser R, Ayouba A, Peeters M, de Oliveira T, Alcantara LC, Grossman Z, Sloot P, Otelea D, Paraschiv S, Boucher C, Camacho RJ, Vandamme AM. RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics 2013, 29:1477-1480. 10.1093/bioinformatics/btt162, 23645815.
13. Van Laethem K, Schrooten Y, Dedecker S, Van Heeswijck L, Deforche K, Van Wijngaerden E, Van Ranst M, Vandamme AM. A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes. J Virol Methods 2006, 132:181-186. 10.1016/j.jviromet.2005.10.008, 16271771.
14. Maes B, Schrooten Y, Snoeck J, Derdelinckx I, Van Ranst M, Vandamme AM, Van Laethem K. Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory. J Virol Methods 2004, 119:45-49. 10.1016/j.jviromet.2004.02.005, 15109820.
15. Li G, Verheyen J, Rhee SY, Voet A, Vandamme AM, Theys K. Functional conservation of HIV-1 gag: implications for rational drug design. Retrovirology 2013, 10:126. 10.1186/1742-4690-10-126, 24176092.
16. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clinical infectious diseases 2006, 42:1608-1618. 10.1086/503914, 16652319.
17. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 2002, 7:123-129. 12212924.
18. Storey JD. A direct approach to false discovery rates. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 2002, 64:479-498. 10.1111/1467-9868.00346.
19. de Oliveira T, Engelbrecht S, Janse van Rensburg E, Gordon M, Bishop K, zur Megede J, Barnett SW, Cassol S. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?. J Virol 2003, 77:9422-9430. 10.1128/JVI.77.17.9422-9430.2003, 12915557.
20. Martins AN, Arruda MB, Pires AF, Tanuri A, Brindeiro RM. Accumulation of P(T/S)AP late domain duplications in HIV type 1 subtypes B, C, and F derived from individuals failing ARV therapy and ARV drug-naive patients. AIDS Res Hum Retroviruses 2011, 27:687-692. 10.1089/aid.2010.0282, 21083435.
21. Mo H, Parkin N, Stewart KD, Lu L, Dekhtyar T, Kempf DJ, Molla A. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication. Antimicrob Agents Chemother 2007, 51:732-735. 10.1128/AAC.00690-06, 17101675.
22. Kolli M, Stawiski E, Chappey C, Schiffer CA. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol 2009, 83:11027-11042. 10.1128/JVI.00628-09, 19706699.